Pharma Stocks
-
NewAmsterdam Pharma (NAMS) Alzheimer’s Data Push Puts Fair Value Back In Focus
Alzheimer’s data presentation puts NewAmsterdam Pharma in focus NewAmsterdam Pharma (NasdaqGM:NAMS) is drawing attention after announcing plans to present new…
Read More » -
Supernus Pharmaceuticals (SUPN) Following Shelf Filing Has Its Undervalued Case In Focus
Supernus Pharmaceuticals shelf registration puts potential equity raise in focus Supernus Pharmaceuticals (SUPN) has filed a US$177.52 million shelf registration…
Read More » -
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Choosing between Dyne Therapeutics (DYN +5.87%) and Recursion Pharmaceuticals (RXRX +3.54%) requires balancing the potential of targeted muscle-tissue therapies against…
Read More » -
Pharma Mar, S.A. (BME:PHM) Stock Goes Ex-Dividend In Just Three Days
Pharma Mar, S.A. (BME:PHM) is about to trade ex-dividend in the next 3 days. The ex-dividend date is two business…
Read More » -
Is It Smart To Buy Bliss GVS Pharma Limited (NSE:BLISSGVS) Before It Goes Ex-Dividend?
It looks like Bliss GVS Pharma Limited (NSE:BLISSGVS) is about to go ex-dividend in the next three days. The ex-dividend…
Read More » -
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data
Ascendis Pharma (NasdaqGS:ASND) is back in focus after new Week 104 radiographic data from its pivotal ApproaCH trial of once…
Read More » -
Merck KGaA (XTRA:MRK) Expands Into Precision Cardiology, Is The Upside Already Priced In?
Merck KGaA (XTRA:MRK) has moved deeper into precision cardiology, committing a $50 million upfront payment and a build-to-buy structure with…
Read More » -
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors.…
Read More » -
Dr. Reddy’s Lab jumps 2%: Why is this pharma stock rising?
Shares of Dr. Reddy’s Laboratories climbed nearly 2% on the NSE on Thursday after the pharmaceutical major announced an expansion…
Read More » -
Has Island Pharmaceuticals (ASX:ILA) More Growth Ahead After a 164% One-Year Rally?
Highlights • Island Pharmaceuticals shares have risen more than 164% over the past year. • The company’s antiviral drug development…
Read More »